about
Dipeptidyl peptidase-4 and kidney fibrosis in diabetesAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesOral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control?Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patientsGLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?The potential role of incretin therapy in the hospital setting.Clinical pharmacokinetics and pharmacodynamics of linagliptin.Incretin-based therapies in prediabetes: Current evidence and future perspectivesLiraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.Incretin-based medications for type 2 diabetes: an overview of reviews.The role of incretin therapy at different stages of diabetes.Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort.Dual actions of a novel bifunctional compound to lower glucose in mice with diet-induced insulin resistanceRenoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR).Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trialA review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.GLP-1 based therapies: differential effects on fasting and postprandial glucose.Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes.Diabetes and beta cell function: from mechanisms to evaluation and clinical implications.Implications of incretin-based therapies on cardiovascular disease.Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies.Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms.Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs.Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
P2860
Q26766089-09E16A3A-E65C-4D20-AD3B-612B9EDA5D24Q26785454-28D6190E-443C-481C-A168-A7B8F25645ADQ27023585-3F9A948F-BA69-4AE9-A3F8-804961A9E3CCQ33607811-8852E5E9-CCF3-450B-AA77-5CDFAD5AB576Q33734024-97C16C64-D4A1-499E-8841-5913F9221166Q33792390-8B763C2A-88DB-43D1-9E20-26BDF1A49A13Q34638128-ABDDB46F-1F5D-4608-937D-27AC4885DD5FQ34699191-E8D35DCD-1E33-42DD-8212-C1F10F2FBCE8Q35055133-5F68EDFF-30EB-4DFD-931F-0A708F847B70Q35577601-0D400EBB-659E-4781-BF4D-23039C30C3BEQ35760288-24259A6C-D599-4815-BA73-D11C3D5A8A30Q35898200-756D9449-54B8-4E0A-8230-D5689258E859Q35916836-EE2ACFF9-42DB-4A82-ACDA-1D2A032DA4E3Q37056839-5EF10563-AB44-4927-9B06-38C625490FCFQ37176743-283B4593-1ECA-4FB9-BCF3-F1A820328F77Q37348976-33930AC4-F47E-4F77-8163-33B022C668C7Q37588842-6853B952-A71B-445A-8D8D-B8B00B4DDD3EQ37659673-3211D887-C4B6-4C95-9677-1DF693D65F5BQ37974712-AAECACCD-4A70-44F9-BE34-E9058B10C849Q38015162-8E5FE3FA-734D-4F1F-B7AA-7F5F1BB054E3Q38129446-F97D625D-6348-4D50-B246-3D5BFC0D3B20Q38165184-1C4882C6-2FC9-4B80-B2C9-793E13257B99Q38264374-6DFA10E0-36F2-4A8D-A5F7-FF5E3FFC41A4Q38442816-DF20B938-09E7-4610-AB1D-88BB42C3C1E8Q39101008-ED42758F-6C77-484C-9F43-AC2FF544DACAQ42175983-051BB140-8C40-471C-BBEE-FA6C039CBC45Q42463784-6E4C591F-B16A-42DF-95B5-9B55D595D5F6Q46924880-E2DFE3EC-7E1E-4064-9CA1-F188569D1084Q57125138-2246EB60-C4FD-49D2-B15C-340AFD1623AE
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Therapy in the early stage: incretins.
@en
type
label
Therapy in the early stage: incretins.
@en
prefLabel
Therapy in the early stage: incretins.
@en
P2860
P921
P356
P1433
P1476
Therapy in the early stage: incretins.
@en
P2093
Itamar Raz
Simona Cernea
P2860
P304
P356
10.2337/DC11-S223
P407
P478
34 Suppl 2
P5008
P577
2011-05-01T00:00:00Z